KFAS
INMB icon

Keating Financial Advisory Services’s INmune Bio INMB Stock Holding History

Keating Financial Advisory Services’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326 Hold
200
– – ﹤0.01% 2392
2026
Q1 		$226 Hold
200
– – ﹤0.01% 2363
2025
Q4 		$312 Buy
+200
New +$357 ﹤0.01% 2015

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Keating Financial Advisory Services's INMB Position: Q2 2026 in Review

Keating Financial Advisory Services held its INmune Bio (INMB) position steady in Q2 2026 at 200 shares worth $326. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Keating Financial Advisory Services first reported a position in INMB in Q4 2025 and has held it in 3 quarters since. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Keating Financial Advisory Services held 200 shares of INmune Bio worth $326 as of Q2 2026.
  • Keating Financial Advisory Services left its INmune Bio share count unchanged in Q2 2026.
  • INmune Bio made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2392 holding.
  • Keating Financial Advisory Services first reported a position in INmune Bio in Q4 2025 and has held it in 3 quarters since.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.